Breast imaging technologies are used for the early detection of breast-related disorders. These technologies are mainly used to detect breast cancer at its initial stages. Various imaging modalities such as mammography, MRI, and ultrasound facilitate in the screening and staging of breast cancer by identifying characteristic masses or calcifications in the breast tissue.
The global breast imaging technologies market is expected to reach $4,502 million by 2022 from $2,544 million in 2015, growing at a CAGR of 8.4% during the forecast period. This market is expected to witness significant growth ahead owing to the increase in incidence of breast cancer globally and rise in initiatives by healthcare organizations to raise awareness about the early detection of breast cancer. The main drivers of the market include the need for technologically advanced products (such automated whole breast ultrasound system (AWBU)) for breast imaging and favorable reimbursement scenario. However, high cost of these imaging modalities and stringent regulatory approval processes hamper the market growth.
The breast imaging technologies market is segmented on the basis of product type and geography. Based on product type, it is bifurcated into ionizing breast imaging and non-ionizing breast imaging technologies. Ionizing breast imaging technologies include analog mammography, full-field digital mammography, 3D breast tomosynthesis, positron emission tomography/computed tomography (PET/CT), molecular breast imaging/breast-specific gamma imaging (MBI/BSGI), cone beam computed tomography (CBCT), and positron emission mammography (PEM). On the other hand, non-ionizing breast imaging technologies are further divided into breast MRI, breast ultrasound, optical imaging, whole breast ultrasound, and breast thermography. The market is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.
Prominent players adopted product development (including product launches and approvals) as their key developmental strategy for expanding their product portfolio. For instance, in June 2014, GE Healthcare received FDA approval of Invenia ABUS, which is an automated breast ultrasound system used for breast cancer detection. This system helps in detecting breast cancer in women with dense tissue when used as an adjunct with a mammogram.
Key benefits
This report provides an extensive analysis of the current and emerging market trends and dynamics from 2014 to 2022 in the global breast imaging technologies market.
Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities across the geographies and predict the competitive environment.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- and country-wise breast imaging market conditions are comprehensively analyzed.
Key market segments
By Product Type
Ionizing Breast Imaging Technologies
Analog Mammography
Full-Field Digital Mammography (FFDM)
3D Breast Tomosynthesis
Positron Emission Tomography/Computed Tomography (Pet/CT)
Molecular Breast Imaging/Breast-Specific Gamma Imaging (MBI/BSGI)
Cone Beam Computed Tomography (CBCT)
Positron Emission Mammography (PEM)
Non-Ionizing Breast Imaging Technologies
Breast MRI
Breast Ultrasound
Optical Imaging
Automated Whole Breast Ultrasound (AWBU)
Breast Thermography
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
The key players profiled in this report are as follows:
Dilon Technologies, Inc.
FUJIFILM Holdings Corporation
Gamma Medica, Inc.
General Electric Company
Hologic, Inc.
Koning Corporation
Koninklijke Philips N.V.
Siemens AG
Sonocine, Inc.
Toshiba corporation
Other players operating in the breast imaging technologies (not elaborated in the report) market include:
Aurora Imaging Technology, Inc.
Carestream Health
Delphinus Medical Technologies, Inc.
Micrima Limited
Tualatin Imaging, P.C.
